137 related articles for article (PubMed ID: 35267497)
1. Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
Fumet JD; Lardenois E; Ray-Coquard I; Harter P; Joly F; Canzler U; Truntzer C; Tredan O; Liebrich C; Lortholary A; Pissaloux D; Leary A; Pfisterer J; Eeckhoutte A; Hilpert F; Fabbro M; Caux C; Alexandre J; Houlier A; Sehouli J; Sohier E; Kimmig R; Dubois B; Spaeth D; Treilleux I; Frenel JS; Herwig U; Le Saux O; Bendriss-Vermare N; du Bois A
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267497
[TBL] [Abstract][Full Text] [Related]
2. Biomarker Assessment of HR Deficiency, Tumor
Stronach EA; Paul J; Timms KM; Hughes E; Brown K; Neff C; Perry M; Gutin A; El-Bahrawy M; Steel JH; Liu X; Lewsley LA; Siddiqui N; Gabra H; Lanchbury JS; Brown R
Mol Cancer Res; 2018 Jul; 16(7):1103-1111. PubMed ID: 29724815
[TBL] [Abstract][Full Text] [Related]
3. Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
Jönsson JM; Bååth M; Björnheden I; Sahin ID; Måsbäck A; Hedenfalk I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33445465
[TBL] [Abstract][Full Text] [Related]
4. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.
Lecuelle J; Boidot R; Mananet H; Derangère V; Albuisson J; Goussot V; Arnould L; Tharin Z; Ray Coquard I; Ghiringhelli F; Truntzer C; Fumet JD
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503204
[TBL] [Abstract][Full Text] [Related]
5. Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
van Wagensveld L; van Baal JOAM; Timmermans M; Gaillard D; Borghuis L; Coffelt SB; Rosenberg EH; Lok CAR; Nijman HW; Kooreman LFS; Sanders J; de Bruijn M; Wessels LFA; van der Wiel R; Rausch C; Broeks A; Kruitwagen RFPM; van der Aa MA; Sonke GS; Schouten PC; Van de Vijver KK; Horlings HM
Cancers (Basel); 2022 Dec; 14(23):. PubMed ID: 36497449
[TBL] [Abstract][Full Text] [Related]
6. Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders.
Yang C; Zhang Z; Tang X; Zhang X; Chen Y; Hu T; Zhang H; Guan M; Zhang X; Wu Z
Hum Cell; 2022 Jan; 35(1):199-213. PubMed ID: 34628623
[TBL] [Abstract][Full Text] [Related]
7. Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
Su R; Liu Y; Wu X; Xiang J; Xi X
Front Mol Biosci; 2021; 8():762741. PubMed ID: 34869593
[No Abstract] [Full Text] [Related]
8. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
11. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Ray-Coquard I; Cibula D; Mirza MR; Reuss A; Ricci C; Colombo N; Koch H; Goffin F; González-Martin A; Ottevanger PB; Baumann K; Bjørge L; Lesoin A; Burges A; Rosenberg P; Gropp-Meier M; Harrela M; Harter P; Frenel JS; Minarik T; Pisano C; Hasenburg A; Merger M; du Bois A;
Int J Cancer; 2020 Jan; 146(2):439-448. PubMed ID: 31381147
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of tumor PD-L1 expression combined with CD8
Wang Q; Lou W; Di W; Wu X
Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
[TBL] [Abstract][Full Text] [Related]
13. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency serves as a prognostic biomarker in clear cell renal cell carcinoma.
He L; Gao F; Zhu J; Xu Q; Yu Q; Yang M; Huang Y
Exp Ther Med; 2023 Sep; 26(3):429. PubMed ID: 37602311
[TBL] [Abstract][Full Text] [Related]
15. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Swisher EM; Aghajanian C; O'Malley DM; Fleming GF; Kaufmann SH; Levine DA; Birrer MJ; Moore KN; Spirtos NM; Shahin MS; Reid TJ; Friedlander M; Steffensen KD; Okamoto A; Sehgal V; Ansell PJ; Dinh MH; Bookman MA; Coleman RL
Gynecol Oncol; 2022 Feb; 164(2):245-253. PubMed ID: 34906376
[TBL] [Abstract][Full Text] [Related]
16. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
[TBL] [Abstract][Full Text] [Related]
17. Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.
Lee YJ; Kim D; Shim JE; Bae SJ; Jung YJ; Kim S; Lee H; Kim SH; Jo SB; Lee JY; Kim HS; Paik S
Int J Cancer; 2020 Apr; 146(7):1851-1861. PubMed ID: 31603993
[TBL] [Abstract][Full Text] [Related]
18. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
20. Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
Zhang M; Ma SC; Tan JL; Wang J; Bai X; Dong ZY; Zhang QX
Front Oncol; 2021; 11():772604. PubMed ID: 34976815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
